BioCentury | Oct 7, 2020
Finance

With life sciences now a ‘core’ investment area, General Atlantic picks a global head

...an observer at companies including Turning Point Therapeutics Inc. (NASDAQ:TPTX), ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) and Peloton Therapeutics Inc....
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

...that it acquired through its takeout of Peloton Therapeutics Inc....
BioCentury | Sep 23, 2020
Management Tracks

Gilead BD head Bender takes top job at pediatric cancer start-up Day One

...an expanded management team that now includes Genentech veteran Lisa Bowers and the addition of former Peloton Therapeutics Inc....
BioCentury | Mar 18, 2020
Finance

March 17 Quick Takes: Tempus, Circle, Immatics, Exuma, CFIUS

...Svennilson and Nextech’s Thilo Schroeder joined Circle’s board, and John Josey, who was CEO of Peloton Therapeutics Inc....
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

...made a pair of multibillion-dollar bolt-on acquisitions, taking out ArQule Inc. for $2.7 billion and Peloton Therapeutics Inc....
BioCentury | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

...Inc. (NASDAQ:BBIO) hired Eli Wallace as CSO in residence for oncology. Wallace was CSO of Peloton Therapeutics Inc....
BioCentury | Nov 18, 2019

Ibrance boosts effect of HIF2A inhibition in renal cancer

...product in preclinical through Phase II testing for other solid cancers. Two HIF2A inhibitors from Peloton Therapeutics Inc....
BioCentury | Aug 1, 2019
Financial News

Vida seeking bigger deals, cures with $600M fund

...improve on standard-of-care treatments. For example, another of its exits came from the sale of Peloton Therapeutics Inc....
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

...Inc. (NASDAQ:AMGN) Nuevolution AB (SSE:NUE) 05/21/19 $167.1 NA NA $167.1 Merck & Co. Inc. (NYSE:MRK) Peloton Therapeutics Inc....
BioCentury | May 25, 2019
Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

...slated to start a Phase I/II trial in 1H20 Rather than complete its proposed listing, Peloton Therapeutics Inc....
Items per page:
1 - 10 of 40
BioCentury | Oct 7, 2020
Finance

With life sciences now a ‘core’ investment area, General Atlantic picks a global head

...an observer at companies including Turning Point Therapeutics Inc. (NASDAQ:TPTX), ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) and Peloton Therapeutics Inc....
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

...that it acquired through its takeout of Peloton Therapeutics Inc....
BioCentury | Sep 23, 2020
Management Tracks

Gilead BD head Bender takes top job at pediatric cancer start-up Day One

...an expanded management team that now includes Genentech veteran Lisa Bowers and the addition of former Peloton Therapeutics Inc....
BioCentury | Mar 18, 2020
Finance

March 17 Quick Takes: Tempus, Circle, Immatics, Exuma, CFIUS

...Svennilson and Nextech’s Thilo Schroeder joined Circle’s board, and John Josey, who was CEO of Peloton Therapeutics Inc....
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

...made a pair of multibillion-dollar bolt-on acquisitions, taking out ArQule Inc. for $2.7 billion and Peloton Therapeutics Inc....
BioCentury | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

...Inc. (NASDAQ:BBIO) hired Eli Wallace as CSO in residence for oncology. Wallace was CSO of Peloton Therapeutics Inc....
BioCentury | Nov 18, 2019

Ibrance boosts effect of HIF2A inhibition in renal cancer

...product in preclinical through Phase II testing for other solid cancers. Two HIF2A inhibitors from Peloton Therapeutics Inc....
BioCentury | Aug 1, 2019
Financial News

Vida seeking bigger deals, cures with $600M fund

...improve on standard-of-care treatments. For example, another of its exits came from the sale of Peloton Therapeutics Inc....
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

...Inc. (NASDAQ:AMGN) Nuevolution AB (SSE:NUE) 05/21/19 $167.1 NA NA $167.1 Merck & Co. Inc. (NYSE:MRK) Peloton Therapeutics Inc....
BioCentury | May 25, 2019
Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

...slated to start a Phase I/II trial in 1H20 Rather than complete its proposed listing, Peloton Therapeutics Inc....
Items per page:
1 - 10 of 40